Interestingly, the difference in lipid profile between ACPA positive and ACPA negative individuals in both the preclinical arthritis and non-arthritis group might also indicate that ACPA itself plays a role in lipid metabolism changes and CVD risk. The gene discussed is PRTN3; the disease is arthritic joint disease.